title: Drug discovery in a multidimensional world: systems, patterns, and networks.
abstract: Despite great strides in revealing and understanding the physiological and molecular bases of cardiovascular disease, efforts to translate this understanding into needed therapeutic interventions continue to lag far behind the initial discoveries. Although pharmaceutical companies continue to increase investments into research and development, the number of drugs gaining federal approval is in decline. Many factors underlie these trends, and a vast number of technological and scientific innovations are being sought through efforts to reinvigorate drug discovery pipelines. Recent advances in molecular profiling technologies and development of sophisticated computational approaches for analyzing these data are providing new, systems-oriented approaches towards drug discovery. Unlike the traditional approach to drug discovery which is typified by a one-drug-one-target mindset, systems-oriented approaches to drug discovery leverage the parallelism and high-dimensionality of the molecular data to construct more comprehensive molecular models that aim to model broader bimolecular systems. These models offer a means to explore complex molecular states (e.g., disease) where thousands to millions of molecular entities comprising multiple molecular data types (e.g., proteomics and gene expression) can be evaluated simultaneously as components of a cohesive biomolecular system. In this paper, we discuss emerging approaches towards systems-oriented drug discovery and contrast these efforts with the traditional, unidimensional approach to drug discovery. We also highlight several applications of these system-oriented approaches across various aspects of drug discovery, including target discovery, drug repositioning and drug toxicity. When available, specific applications to cardiovascular drug discovery are highlighted and discussed.
authors.affiliation: Program in Biomedical Informatics, Stanford University School of Medicine, Stanford, CA, USA.
authors.forename: Joel T
authors.initials: JT
authors.lastname: Dudley
authors.forename: Eric
authors.initials: E
authors.lastname: Schadt
authors.forename: Marina
authors.initials: M
authors.lastname: Sirota
authors.forename: Atul J
authors.initials: AJ
authors.lastname: Butte
authors.forename: Euan
authors.initials: E
authors.lastname: Ashley
mesh_terms: D000818:Animals; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000235:genetics; D004059:Diffusion of Innovation; D055808:Drug Discovery / Q000379:methods*; D058492:Drug Repositioning; D053263:Gene Regulatory Networks; D023281:Genomics; D005838:Genotype; D006801:Humans; D008954:Models, Biological; D058990:Molecular Targeted Therapy; D010363:Pattern Recognition, Automated; D010641:Phenotype; D018570:Risk Assessment; D049490:Systems Biology; D057170:Translational Research, Biomedical
chemical_list: D002317:Cardiovascular Agents